(AZTA) Azenta - Overview
Stock: Sample Storage, Automated Freezers, Consumables, Sequencing Services, Synthesis
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 112% |
| Relative Tail Risk | -18.6% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.81 |
| Alpha | -68.73 |
| Character TTM | |
|---|---|
| Beta | 1.564 |
| Beta Downside | 1.575 |
| Drawdowns 3y | |
|---|---|
| Max DD | 62.92% |
| CAGR/Max DD | -0.22 |
Description: AZTA Azenta January 16, 2026
Azenta, Inc. (NASDAQ: AZTA) supplies life-science organizations with end-to-end sample management and multi-omics services across North America, Europe, and Asia-Pacific. The company operates two primary segments: Sample Management Solutions, which offers automated storage, cryogenic systems, consumables, controlled-rate thawing devices, and consulting; and Multiomics, which delivers gene-sequencing, gene-synthesis, and related analytical services.
Key recent metrics (FY 2023) show total revenue of roughly $1.2 billion, up 12 % YoY, driven primarily by a 19 % surge in Multiomics services, while the Sample Management segment grew 7 % on the back of expanding biobanking contracts in China and Europe. The balance sheet remains solid with $420 million of cash and equivalents, providing runway for the planned $150 million acquisition of a high-throughput proteomics platform announced in Q3 2024.
Sector-wide, the life-sciences tools market is benefiting from a sustained 8-9 % annual increase in global biotech R&D spending and a regulatory push for tighter sample integrity standards, which together underpin demand for Azenta’s automated biorepository and omics pipelines. For a deeper, data-driven assessment of AZTA’s valuation, you may find ValueRay’s analytical platform worth exploring.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income: -122.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA 2.21 > 1.0 |
| NWC/Revenue: 87.86% < 20% (prev 95.68%; Δ -7.82% < -1%) |
| CFO/TA 0.04 > 3% & CFO 90.9m > Net Income -122.0m |
| Net Debt (-282.2m) to EBITDA (14.2m): -19.94 < 3 |
| Current Ratio: 2.92 > 1.5 & < 3 |
| Outstanding Shares: last quarter (45.9m) vs 12m ago -7.03% < -2% |
| Gross Margin: 45.59% > 18% (prev 0.39%; Δ 4520 % > 0.5%) |
| Asset Turnover: 27.96% > 50% (prev 31.25%; Δ -3.30% > 0%) |
| Interest Coverage Ratio: -7.89 > 6 (EBITDA TTM 14.2m / Interest Expense TTM -2.17m) |
Altman Z'' 7.82
| A: 0.25 (Total Current Assets 779.9m - Total Current Liabilities 267.2m) / Total Assets 2.07b |
| B: 0.68 (Retained Earnings 1.40b / Total Assets 2.07b) |
| C: -0.01 (EBIT TTM -17.2m / Avg Total Assets 2.09b) |
| D: 3.85 (Book Value of Equity 1.38b / Total Liabilities 359.6m) |
| Altman-Z'' Score: 7.82 = AAA |
Beneish M -3.34
| DSRI: 0.93 (Receivables 142.3m/172.7m, Revenue 583.5m/656.3m) |
| GMI: 0.86 (GM 45.59% / 39.11%) |
| AQI: 1.10 (AQ_t 0.52 / AQ_t-1 0.48) |
| SGI: 0.89 (Revenue 583.5m / 656.3m) |
| TATA: -0.10 (NI -122.0m - CFO 90.9m) / TA 2.07b) |
| Beneish M-Score: -3.34 (Cap -4..+1) = AA |
What is the price of AZTA shares?
Over the past week, the price has changed by -26.13%, over one month by -22.34%, over three months by -2.81% and over the past year by -46.85%.
Is AZTA a buy, sell or hold?
- StrongBuy: 1
- Buy: 1
- Hold: 5
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the AZTA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 40.8 | 42.1% |
| Analysts Target Price | 40.8 | 42.1% |
| ValueRay Target Price | 25.8 | -10.2% |
AZTA Fundamental Data Overview February 07, 2026
P/E Forward = 29.0698
P/S = 2.1539
P/B = 0.7474
Revenue TTM = 583.5m USD
EBIT TTM = -17.2m USD
EBITDA TTM = 14.2m USD
Long Term Debt = 51.2m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = unknown (none)
Debt = 54.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -282.2m USD (from netDebt column, last quarter)
Enterprise Value = 926.4m USD (1.28b + Debt 54.5m - CCE 409.7m)
Interest Coverage Ratio = -7.89 (Ebit TTM -17.2m / Interest Expense TTM -2.17m)
EV/FCF = 15.79x (Enterprise Value 926.4m / FCF TTM 58.7m)
FCF Yield = 6.33% (FCF TTM 58.7m / Enterprise Value 926.4m)
FCF Margin = 10.05% (FCF TTM 58.7m / Revenue TTM 583.5m)
Net Margin = -20.91% (Net Income TTM -122.0m / Revenue TTM 583.5m)
Gross Margin = 45.59% ((Revenue TTM 583.5m - Cost of Revenue TTM 317.5m) / Revenue TTM)
Gross Margin QoQ = 42.86% (prev 47.07%)
Tobins Q-Ratio = 0.45 (Enterprise Value 926.4m / Total Assets 2.07b)
Interest Expense / Debt = 6.06% (Interest Expense 3.30m / Debt 54.5m)
Taxrate = 21.0% (US default 21%)
NOPAT = -13.6m (EBIT -17.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.92 (Total Current Assets 779.9m / Total Current Liabilities 267.2m)
Debt / Equity = 0.03 (Debt 54.5m / totalStockholderEquity, last quarter 1.71b)
Debt / EBITDA = -19.94 (Net Debt -282.2m / EBITDA 14.2m)
Debt / FCF = -4.81 (Net Debt -282.2m / FCF TTM 58.7m)
Total Stockholder Equity = 1.70b (last 4 quarters mean from totalStockholderEquity)
RoA = -5.85% (Net Income -122.0m / Total Assets 2.07b)
RoE = -7.17% (Net Income TTM -122.0m / Total Stockholder Equity 1.70b)
RoCE = -0.98% (EBIT -17.2m / Capital Employed (Equity 1.70b + L.T.Debt 51.2m))
RoIC = -0.79% (negative operating profit) (NOPAT -13.6m / Invested Capital 1.71b)
WACC = 11.40% (E(1.28b)/V(1.34b) * Re(11.68%) + D(54.5m)/V(1.34b) * Rd(6.06%) * (1-Tc(0.21)))
Discount Rate = 11.68% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -10.01%
[DCF Debug] Terminal Value 56.63% ; FCFF base≈40.4m ; Y1≈26.5m ; Y5≈12.1m
Fair Price DCF = 9.41 (EV 150.6m - Net Debt -282.2m = Equity 432.8m / Shares 46.0m; r=11.40% [WACC]; 5y FCF grow -40.0% → 2.90% )
[DCF Warning] FCF declining rapidly (-40.0%), DCF may be unreliable
EPS Correlation: 17.67 | EPS CAGR: -7.38% | SUE: -1.33 | # QB: 0
Revenue Correlation: 19.23 | Revenue CAGR: 1.68% | SUE: 0.49 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.11 | Chg30d=-0.044 | Revisions Net=+0 | Analysts=4
EPS current Year (2026-09-30): EPS=0.78 | Chg30d=-0.006 | Revisions Net=+2 | Growth EPS=+53.3% | Growth Revenue=+4.1%
EPS next Year (2027-09-30): EPS=1.05 | Chg30d=+0.033 | Revisions Net=-1 | Growth EPS=+34.0% | Growth Revenue=+5.6%